pembrolizumab

Keytruda combination(Inlyta) found to reduce risk of death in RCC – Renal Cell Carcinoma

A combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) and Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) has been found to reduce risk of death by nearly half compared to sunitinib as first-line treatment for advanced renal cell carcinoma (RCC). The results are taken from the pivotal Phase III KEYNOTE-426 trial, and show that the combination is […]